205 related articles for article (PubMed ID: 30257991)
1. Combining Homologous Recombination and Phosphopeptide-binding Data to Predict the Impact of
Petitalot A; Dardillac E; Jacquet E; Nhiri N; Guirouilh-Barbat J; Julien P; Bouazzaoui I; Bonte D; Feunteun J; Schnell JA; Lafitte P; Aude JC; Noguès C; Rouleau E; Lidereau R; Lopez BS; Zinn-Justin S; Caputo SM;
Mol Cancer Res; 2019 Jan; 17(1):54-69. PubMed ID: 30257991
[No Abstract] [Full Text] [Related]
2. Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.
Lee MS; Green R; Marsillac SM; Coquelle N; Williams RS; Yeung T; Foo D; Hau DD; Hui B; Monteiro AN; Glover JN
Cancer Res; 2010 Jun; 70(12):4880-90. PubMed ID: 20516115
[TBL] [Abstract][Full Text] [Related]
3. Impact of BRCA1 BRCT domain missense substitutions on phosphopeptide recognition.
Coquelle N; Green R; Glover JN
Biochemistry; 2011 May; 50(21):4579-89. PubMed ID: 21473589
[TBL] [Abstract][Full Text] [Related]
4. Pathogenicity of the BRCA1 missense variant M1775K is determined by the disruption of the BRCT phosphopeptide-binding pocket: a multi-modal approach.
Tischkowitz M; Hamel N; Carvalho MA; Birrane G; Soni A; van Beers EH; Joosse SA; Wong N; Novak D; Quenneville LA; Grist SA; ; Nederlof PM; Goldgar DE; Tavtigian SV; Monteiro AN; Ladias JA; Foulkes WD
Eur J Hum Genet; 2008 Jul; 16(7):820-32. PubMed ID: 18285836
[TBL] [Abstract][Full Text] [Related]
5. Structural basis of phosphopeptide recognition by the BRCT domain of BRCA1.
Williams RS; Lee MS; Hau DD; Glover JN
Nat Struct Mol Biol; 2004 Jun; 11(6):519-25. PubMed ID: 15133503
[TBL] [Abstract][Full Text] [Related]
6. Characterization of cancer-linked BRCA1-BRCT missense variants and their interaction with phosphoprotein targets.
Drikos I; Nounesis G; Vorgias CE
Proteins; 2009 Nov; 77(2):464-76. PubMed ID: 19452558
[TBL] [Abstract][Full Text] [Related]
7. A high-throughput functional complementation assay for classification of BRCA1 missense variants.
Bouwman P; van der Gulden H; van der Heijden I; Drost R; Klijn CN; Prasetyanti P; Pieterse M; Wientjens E; Seibler J; Hogervorst FB; Jonkers J
Cancer Discov; 2013 Oct; 3(10):1142-55. PubMed ID: 23867111
[TBL] [Abstract][Full Text] [Related]
8. Characterization of BRCA1 and BRCA2 variants found in a Norwegian breast or ovarian cancer cohort.
Jarhelle E; Riise Stensland HM; Mæhle L; Van Ghelue M
Fam Cancer; 2017 Jan; 16(1):1-16. PubMed ID: 27495310
[TBL] [Abstract][Full Text] [Related]
9. BRCT domains: phosphopeptide binding and signaling modules.
Rodriguez MC; Songyang Z
Front Biosci; 2008 May; 13():5905-15. PubMed ID: 18508631
[TBL] [Abstract][Full Text] [Related]
10. Phosphopeptide interactions with BRCA1 BRCT domains: More than just a motif.
Wu Q; Jubb H; Blundell TL
Prog Biophys Mol Biol; 2015 Mar; 117(2-3):143-148. PubMed ID: 25701377
[TBL] [Abstract][Full Text] [Related]
11. DNA repair-related functional assays for the classification of BRCA1 and BRCA2 variants: a critical review and needs assessment.
Toland AE; Andreassen PR
J Med Genet; 2017 Nov; 54(11):721-731. PubMed ID: 28866612
[TBL] [Abstract][Full Text] [Related]
12. Compromised BRCA1-PALB2 interaction is associated with breast cancer risk.
Foo TK; Tischkowitz M; Simhadri S; Boshari T; Zayed N; Burke KA; Berman SH; Blecua P; Riaz N; Huo Y; Ding YC; Neuhausen SL; Weigelt B; Reis-Filho JS; Foulkes WD; Xia B
Oncogene; 2017 Jul; 36(29):4161-4170. PubMed ID: 28319063
[TBL] [Abstract][Full Text] [Related]
13. A yeast recombination assay to characterize human BRCA1 missense variants of unknown pathological significance.
Caligo MA; Bonatti F; Guidugli L; Aretini P; Galli A
Hum Mutat; 2009 Jan; 30(1):123-33. PubMed ID: 18680205
[TBL] [Abstract][Full Text] [Related]
14. Inter-BRCT linker is probably the most intolerant region of the BRCA1 BRCT domain.
Yadegari F; Farahmand L; Esmaeili R; Zarinfam S; Majidzadeh-A K
J Biomol Struct Dyn; 2024 Jul; 42(11):5734-5746. PubMed ID: 37948190
[TBL] [Abstract][Full Text] [Related]
15. Collective evidence supports neutrality of BRCA1 V1687I, a novel sequence variant in the conserved THV motif of the first BRCT repeat.
Cortesi L; De Nicolo A; Medici V; Marino M; Turchetti D; Pradella LM; Rossi G; Parisini E; Federico M
Breast Cancer Res Treat; 2012 Jul; 134(1):435-41. PubMed ID: 22527099
[TBL] [Abstract][Full Text] [Related]
16. Multimodal assessment of protein functional deficiency supports pathogenicity of BRCA1 p.V1688del.
De Nicolo A; Parisini E; Zhong Q; Dalla Palma M; Stoeckert KA; Domchek SM; Nathanson KL; Caligo MA; Vidal M; Cusick ME; Garber JE
Cancer Res; 2009 Sep; 69(17):7030-7. PubMed ID: 19706752
[TBL] [Abstract][Full Text] [Related]
17. Phosphopeptide binding specificities of BRCA1 COOH-terminal (BRCT) domains.
Rodriguez M; Yu X; Chen J; Songyang Z
J Biol Chem; 2003 Dec; 278(52):52914-8. PubMed ID: 14578343
[TBL] [Abstract][Full Text] [Related]
18. Missense mutations of BRCA1 gene affect the binding with p53 both in vitro and in vivo.
Quaresima B; Faniello MC; Baudi F; Crugliano T; Di Sanzo M; Cuda G; Costanzo F; Venuta S
Oncol Rep; 2006 Oct; 16(4):811-5. PubMed ID: 16969499
[TBL] [Abstract][Full Text] [Related]
19. Expression of cancer related BRCA1 missense variants decreases MMS-induced recombination in Saccharomyces cerevisiae without altering its nuclear localization.
Lodovichi S; Vitello M; Cervelli T; Galli A
Cell Cycle; 2016 Oct; 15(20):2723-31. PubMed ID: 27484786
[TBL] [Abstract][Full Text] [Related]
20. Effects on human transcriptome of mutated BRCA1 BRCT domain: a microarray study.
Iofrida C; Melissari E; Mariotti V; Guglielmi C; Guidugli L; Caligo MA; Pellegrini S
BMC Cancer; 2012 May; 12():207. PubMed ID: 22646717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
